Caleres’s (NYSE:CAL) Q1 CY2026 Sales Top Estimates

Caleres (NYSE:CAL) reported Q1 CY2026 revenue of $666.6 million, up 8.5% year over year and 1.3% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.38, 2.7% above consensus. The article notes operating margin improved to 3.6% and that shares rose 3.6% to $14.62 after results.

Original reporting
Published Jun 4, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Caleres’s (NYSE:CAL) Q1 CY2026 Sales Top Estimates — source image
Decision brief

The 30-second read

$CALNeutralMed
01

Why it matters

Q1 results beat estimates (revenue and adjusted EPS) and operating margin improved, but the forward EPS outlook disappointed, making the trade more about guidance durability than the headline beat.

02

Market read

For traders, the key decision point is whether the Q1 beat and margin improvement are likely to translate into renewed EPS upside versus continued guidance pressure.

03

What to watch

The article provides limited detail on what drove the operating margin expansion and does not quantify inventory, promotions, or channel trends that could determine whether guidance recovers.

Relevance 8/10Novelty 8/10Timing: post-Q1 earnings reaction (stock up 3.6% to $14.62 immediately after results)

Background

Caleres (owner of Dr. Scholl’s) is a branded footwear company; the article frames recent performance as slower long-term growth with flat revenue over the prior two years.

Company-level read

Ticker impact

$CALNeutralMedium confidence
Context

Caleres reported Q1 CY2026 revenue of $666.6M (+8.5% YoY) and adjusted EPS $0.38, both ahead of estimates, but guided mixed results.

Expected impact

Likely supports a modestly bullish bias from the earnings beat, but forward-guidance shortfall may cap upside and increase volatility.

Evidence & confidence

The article cites a Q1 beat and operating margin improvement, yet explicitly notes next-quarter EPS guidance missed and full-year EPS guidance fell short of Wall Street.

Market effects

Signals ongoing demand/momentum in branded footwear but highlights margin pressure and the importance of guidance for consumer discretionary names.

No specific regional impacts mentioned.

No explicit global supply/demand or international exposure details provided.

Counterpoint

The stock’s immediate pop despite a guidance miss suggests the market may be discounting forward concerns or focusing on margin efficiency improvements.

Key entities

  • Caleres

    Reported Q1 CY2026 revenue and adjusted EPS beats; operating margin improved; next-quarter and full-year EPS guidance missed.

Related articles

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.

$UNITMed

Uniti (UNIT) Q2 2026 Earnings Call Transcript

Uniti (UNIT) held its Q2 2026 earnings call, saying demand was strong across categories and highlighting growth in fiber revenue. The company reported total fiber revenue up 10% year over year and Fiber Infrastructure fiber revenue up 6%. Uniti raised its 2026 outlook for new fiber homes to 475,000 to 525,000 and said managed services attachment rose, with 16% of new bookings including it.